KR101699581B1 - 시트르산염 및 중탄산염을 포함하는 제약 조성물 및 시스틴뇨증을 치료하기 위한 그것의 용도 - Google Patents

시트르산염 및 중탄산염을 포함하는 제약 조성물 및 시스틴뇨증을 치료하기 위한 그것의 용도 Download PDF

Info

Publication number
KR101699581B1
KR101699581B1 KR1020137015579A KR20137015579A KR101699581B1 KR 101699581 B1 KR101699581 B1 KR 101699581B1 KR 1020137015579 A KR1020137015579 A KR 1020137015579A KR 20137015579 A KR20137015579 A KR 20137015579A KR 101699581 B1 KR101699581 B1 KR 101699581B1
Authority
KR
South Korea
Prior art keywords
composition
formulation
agent
weight
bicarbonate
Prior art date
Application number
KR1020137015579A
Other languages
English (en)
Korean (ko)
Other versions
KR20130119450A (ko
Inventor
카트린 귀떼
뤽-앙드레 그라니어
카롤린 루셀-므페티
Original Assignee
아드비센
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101699581(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아드비센 filed Critical 아드비센
Publication of KR20130119450A publication Critical patent/KR20130119450A/ko
Application granted granted Critical
Publication of KR101699581B1 publication Critical patent/KR101699581B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137015579A 2010-11-18 2011-11-18 시트르산염 및 중탄산염을 포함하는 제약 조성물 및 시스틴뇨증을 치료하기 위한 그것의 용도 KR101699581B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1059474 2010-11-18
FR1059474A FR2967578B1 (fr) 2010-11-18 2010-11-18 Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
PCT/FR2011/052697 WO2012066257A1 (fr) 2010-11-18 2011-11-18 Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie

Publications (2)

Publication Number Publication Date
KR20130119450A KR20130119450A (ko) 2013-10-31
KR101699581B1 true KR101699581B1 (ko) 2017-01-24

Family

ID=44146941

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137015579A KR101699581B1 (ko) 2010-11-18 2011-11-18 시트르산염 및 중탄산염을 포함하는 제약 조성물 및 시스틴뇨증을 치료하기 위한 그것의 용도

Country Status (16)

Country Link
US (1) US9636304B2 (fr)
EP (1) EP2640363B1 (fr)
JP (1) JP5879359B2 (fr)
KR (1) KR101699581B1 (fr)
AU (1) AU2011331019B2 (fr)
CA (1) CA2816660C (fr)
DK (1) DK2640363T3 (fr)
ES (1) ES2553424T3 (fr)
FR (2) FR2967578B1 (fr)
HU (1) HUE026230T2 (fr)
IL (1) IL226373A (fr)
MX (1) MX338975B (fr)
NZ (1) NZ611026A (fr)
PL (1) PL2640363T3 (fr)
WO (1) WO2012066257A1 (fr)
ZA (1) ZA201303695B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11273140B2 (en) * 2013-06-06 2022-03-15 Stefanie A. Seixas-Mikelus Juice beverage for prevention and treatment of renal stones
FR3009496B1 (fr) * 2013-08-12 2016-02-05 Mohamed Skiba Formes multiparticulaires a liberation prolongee, procede de leurs preparations et compositions les contenant pour le traitement et/ou prevention de la cyctinurie
US20210145777A1 (en) * 2017-06-16 2021-05-20 Altibio, Inc. Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
AU2022333240A1 (en) 2021-08-24 2024-03-28 Laminaria Group Ab Sodium bicarbonate nutritional supplement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1970066A1 (fr) 2007-03-12 2008-09-17 Medice Arzneimittel Pütter GmbH & Co. KG Composition pharmaceutique destinée au traitement d'une hyperacidification du sang

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903255A (en) * 1971-05-17 1975-09-02 Rohm & Haas Effervescent potassium chloride tablet
HU165181B (fr) 1971-11-08 1974-07-27
US4451454A (en) * 1981-06-16 1984-05-29 Wong Dennis W Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
GB2130087A (en) 1982-09-22 1984-05-31 Dr Joachime Helbig Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions
JPS60197624A (ja) * 1984-03-21 1985-10-07 Nippon Chemiphar Co Ltd 尿アルカリ化性食品組成物
CA1326040C (fr) 1989-11-16 1994-01-11 Neill B. Walsdorf Citrate de magnesium-potassium
JP2941163B2 (ja) * 1993-02-19 1999-08-25 武田薬品工業株式会社 ペットの尿結石症治療・予防剤および治療方法
US5674529A (en) * 1995-06-06 1997-10-07 Church & Dwight Co., Inc. Alkalinizing potassium salt controlled release preparations
US5888544A (en) * 1996-06-20 1999-03-30 Gerhard Gergely Effervescent system for effervescent tablets and effervescent granules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1970066A1 (fr) 2007-03-12 2008-09-17 Medice Arzneimittel Pütter GmbH & Co. KG Composition pharmaceutique destinée au traitement d'une hyperacidification du sang

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Goldfarb, DS, Urinary Alkalization, Cystinuria support network, 2008.9.27.

Also Published As

Publication number Publication date
AU2011331019B2 (en) 2016-04-07
JP2013542975A (ja) 2013-11-28
CA2816660C (fr) 2017-07-04
FR21C1049I1 (fr) 2021-12-10
ZA201303695B (en) 2014-07-30
FR2967578B1 (fr) 2012-12-28
NZ611026A (en) 2014-12-24
PL2640363T3 (pl) 2016-01-29
FR2967578A1 (fr) 2012-05-25
WO2012066257A1 (fr) 2012-05-24
AU2011331019A1 (en) 2013-06-13
MX2013005482A (es) 2013-08-29
ES2553424T3 (es) 2015-12-09
FR21C1049I2 (fr) 2022-09-30
MX338975B (es) 2016-05-06
US20130236545A1 (en) 2013-09-12
JP5879359B2 (ja) 2016-03-08
IL226373A (en) 2016-04-21
US9636304B2 (en) 2017-05-02
EP2640363B1 (fr) 2015-08-26
KR20130119450A (ko) 2013-10-31
HUE026230T2 (en) 2016-06-28
IL226373A0 (en) 2013-07-31
EP2640363A1 (fr) 2013-09-25
CA2816660A1 (fr) 2012-05-24
DK2640363T3 (en) 2015-12-14

Similar Documents

Publication Publication Date Title
US8025897B2 (en) Ibuprofen composition
ES2380747T3 (es) Métodos y medicamentos para administración de ibuprofeno
MX2011007399A (es) Suspension farmaceutica de liberacion doble.
US20110135723A1 (en) Pharmaceutical compositions containing pregabalin
KR101699581B1 (ko) 시트르산염 및 중탄산염을 포함하는 제약 조성물 및 시스틴뇨증을 치료하기 위한 그것의 용도
JP6386011B2 (ja) クレブス回路前駆体塩、特にクエン酸塩を含んでなる医薬組成物、及び医薬としてのこれらの使用
AU2006230557A1 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
US9662296B2 (en) Pharmaceutical composition comprising bicarbonate salt, and use thereof as a medicament in the treatment and/or prevention of urinary lithiases and related diseases
US20060198886A1 (en) Medicament having coated methenamine combined with acidifier
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
US20070065511A1 (en) Controlled delivery creatine formulations and method of using the same
ES2317450T3 (es) Formulacion de liberacion controlada de acido valproico y sus derivados.
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
RU2669920C2 (ru) Фармацевтическая композиция с контролируемым высвобождением, основанная на прионовой кислоте
ES2915026T3 (es) Composiciones farmacéuticas que comprenden safinamida
JP2009525953A (ja) ジバルプロ酸及びその誘導体の徐放性製剤
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
CA3202758A1 (fr) Formulation orale solide pour le nettoyage du colon
TR2022013356A2 (tr) Oral terapöti̇k formülasyonlar
KR20230044355A (ko) 미로가발린베실산염을 함유하는 구강내 붕괴정
Karumanchi Formulation Development and Evaluation of Deferasirox Dispersible Tablets

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20191218

Year of fee payment: 4